基本信息
views: 22
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Research interest
We investigate immunoregulatory mechanisms to identify biomarkers of immune disease and targets for immunotherapy. Our focus is on type 1 diabetes (T1D) as a paradigm for the pre-clinical diagnosis, prediction and prevention of autoimmune disease; we also study immune-inflammatory mechanisms in type 2 diabetes (T2D).
After demonstrating the primacy of insulin as an autoantigen driving pancreatic beta-cell destruction in T1D, and its application as a therapeutic tool to induce regulatory anti-diabetogenic T cells, we have conducted a series of trials to determine if a nasal insulin vaccine will prevent T1D in humans. To better understand environment-gene interactions in T1D we are undertaking microbiome, metabolome, epigenome and immunome studies of mothers during pregnancy and their T1D at-risk infants though early life.
Recently, we described a novel immunoregulatory mechanism whereby soluble CD52, released from activated T cells, suppresses other T cells and innate immune cells via Siglec receptor pathways. The therapeutic potential of CD52-Fc is being investigated.
We investigate immunoregulatory mechanisms to identify biomarkers of immune disease and targets for immunotherapy. Our focus is on type 1 diabetes (T1D) as a paradigm for the pre-clinical diagnosis, prediction and prevention of autoimmune disease; we also study immune-inflammatory mechanisms in type 2 diabetes (T2D).
After demonstrating the primacy of insulin as an autoantigen driving pancreatic beta-cell destruction in T1D, and its application as a therapeutic tool to induce regulatory anti-diabetogenic T cells, we have conducted a series of trials to determine if a nasal insulin vaccine will prevent T1D in humans. To better understand environment-gene interactions in T1D we are undertaking microbiome, metabolome, epigenome and immunome studies of mothers during pregnancy and their T1D at-risk infants though early life.
Recently, we described a novel immunoregulatory mechanism whereby soluble CD52, released from activated T cells, suppresses other T cells and innate immune cells via Siglec receptor pathways. The therapeutic potential of CD52-Fc is being investigated.
Research Interests
Papers共 594 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
DIABETES TECHNOLOGY & THERAPEUTICSno. 2 (2024): 87-94
Jessica G Borger,Ashley P Ng, Holly Anderton, George W Ashdown, Megan Auld,Marnie E Blewitt, Daniel V Brown,Melissa J Call, Peter Collins,Saskia Freytag,Leonard C Harrison, Eva Hesping,
Annals of Medicineno. 1 (2023): 2198255-2198255
Journal of Diabetes Investigationno. 9 (2023): 1092-1100
The Journal of allergy and clinical immunologyno. 3 (2023): 667-675
EUROPEAN RESPIRATORY JOURNAL (2023)
The New England journal of medicineno. 23 (2023): 2140-2150
NEW ENGLAND JOURNAL OF MEDICINEno. 23 (2023): 2140-2150
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn